Home Featured Page 102

Featured

Latest

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on the First Patients, Payers and Practicalities

Out of This World: Why AI Belongs Beside the Therapist

Psychedelic Policy Briefing: June 11, 2026

May 2026 Psychedelic Bill Roundup

Cedar Clinical Research, by Numinus, the top enrolling clinical research site...

Algernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in...

Psychedelics Weekly – Drug Testing and Harm Reduction, Ketamine vs. ECT,...

Terran Biosciences announces exclusive licensing deal with Pierre Fabre for idazoxan;...

Silo Pharma Announces Participation on Webull Corporate Communications Service Platform

Numinus to Participate in a Water Tower Research Fireside Chat on...

Reunion Neuroscience Announces US$13.1 Million Take-Private Transaction with MPM BioImpact

atai Life Sciences to Participate in Upcoming June Investor Conferences

BREAKING: State of Kentucky Sets aside $42 Million for Psychedelic Research,...

Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office...

EDITOR PICKS

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on...

Out of This World: Why AI Belongs Beside the Therapist

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on the First Patients, Payers and Practicalities

Out of This World: Why AI Belongs Beside the Therapist

Shroomski Melt

Psychedelic Policy Briefing: June 11, 2026

May 2026 Psychedelic Bill Roundup

Cedar Clinical Research, by Numinus, the top enrolling clinical research site...

Algernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in...

Psychedelics Weekly – Drug Testing and Harm Reduction, Ketamine vs. ECT,...

Terran Biosciences announces exclusive licensing deal with Pierre Fabre for idazoxan;...

Silo Pharma Announces Participation on Webull Corporate Communications Service Platform

Numinus to Participate in a Water Tower Research Fireside Chat on...

Reunion Neuroscience Announces US$13.1 Million Take-Private Transaction with MPM BioImpact

atai Life Sciences to Participate in Upcoming June Investor Conferences

BREAKING: State of Kentucky Sets aside $42 Million for Psychedelic Research,...

Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office...

EDITOR PICKS

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on...

Out of This World: Why AI Belongs Beside the Therapist

Shroomski Melt

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY